MedTrace Logo

Immunogenic Cell Death as a Novel Mechanism of Mitomycin C Activity in Bladder Cancer

NCT04256616 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2020-07-07

No results posted yet for this study

Summary

The principal objective of this study consists in the assessment of Immunogenic Cell Death (ICD) induction in neoplastic tissues derived from bladder cancer patients treated ex vivo with Mitomycin C (MMC). The evaluation is performed using cellular and molecular analyses of treated versus untreated samples derived from the same patient

Conditions

Interventions

OTHER

This is an observational study that does not concern a direct intervention on patients and control subjects and does not interfere with the clinical management of patients.

urine collection: DNA is isolated from urine samples (catheterized, washout, midstream) and the 16S rRNA gene is sequenced. Specimen collection: Specimens collected during TURBT are selected by a pathologist and trasferred to the laboratory. The tissues are treated ex vivo with MMC.

Sponsors & Collaborators

  • Istituto Clinico Humanitas

    lead OTHER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-27
Primary Completion
2020-09-01
Completion
2020-09-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04256616 on ClinicalTrials.gov